Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-19-005067
Filing Date
2019-01-23
Accepted
2019-01-23 20:45:11
Documents
1
Period of Report
2019-01-18

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 5642
  Complete submission text file 0001209191-19-005067.txt   7968
Mailing Address 201 ELLIOTT AVE. WEST, SUITE 230 SEATTLE WA 98119
Business Address 201 ELLIOTT AVE. WEST, SUITE 230 SEATTLE WA 98119 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Issuer) CIK: 0001626199 (see all company filings)

EIN.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, PO BOX 309 GRAND CAYMAN E9 KY1-1104 345-949-8066
Decheng Capital China Life Sciences USD Fund III, L.P. (Reporting) CIK: 0001736814 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-37449 | Film No.: 19538491

Mailing Address UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 345-949-8066
Decheng Capital Management III (Cayman), LLC (Reporting) CIK: 0001747821 (see all company filings)

State of Incorp.: E9 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-37449 | Film No.: 19538492